v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
REVENUES:        
Product revenue $ 7,751,885 $ 6,525,233 $ 17,915,921 $ 10,018,114
License revenue 35,709 35,709 71,417 71,417
Total Revenues 7,787,594 6,560,942 17,987,338 10,089,531
OPERATING EXPENSES:        
Cost of product revenue (exclusive of amortization expense shown below) 13,495,629 10,491,236 30,324,855 19,896,415
Research and development 1,656,420 516,986 3,185,158 1,387,621
Plasma center operating expenses 877,902 594,113 1,378,546 1,248,599
Amortization of intangible assets 178,838 211,234 357,676 422,469
Selling, general and administrative 8,702,630 6,086,047 16,634,714 11,681,517
Total operating expenses 24,911,419 17,899,616 51,880,949 34,636,621
LOSS FROM OPERATIONS (17,123,825) (11,338,674) (33,893,611) (24,547,090)
OTHER INCOME (EXPENSE):        
Interest and other income 19,411 209,808 267,479 337,207
Interest expense (3,067,306) (2,072,578) (5,784,397) (3,613,085)
Loss on extinguishment of debt 0 0 0 (9,962,495)
Gain on transfer of plasma center assets 0 0 0 11,527,421
Other expense, net (6,371) (10,428) (12,792) (21,785)
Other expense, net (3,054,266) (1,873,198) (5,529,710) (1,732,737)
NET LOSS $ (20,178,091) $ (13,211,872) $ (39,423,321) $ (26,279,827)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.23) $ (0.25) $ (0.49) $ (0.53)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted 86,347,467 52,206,204 80,064,641 49,295,805

Source